Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | BRD2 | P25440 | 2/20 | 0.67 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.67 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16196939 | 0.95 | BRD4 (1.00) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16204738 | 0.89 | BRD4 (1.00) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16204726 | 0.86 | BRD4 (1.00) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16204698 | 0.85 | BRD4 (1.00) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16204694 | 0.85 | BRD4 (1.00) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16197022 | 0.85 | BRD4 (1.00) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16204679 | 0.84 | BRD4 (1.00) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16204684 | 0.82 | BRD4 (1.00) | BRD4BRD2BRD3BRDT | |
| SCHEMBL20892365 | 0.82 | BRD4 (0.81) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16197336 | 0.81 | BRD4 (0.73) | BRD4BRD2BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2989096-B1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BEIGENE LTD (KY) | 2019-04-10 | — | — | EP | disclosed |
| EP-2989096-B1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BEIGENE LTD (KY) | 2019-04-10 | — | — | EP | disclosed |
| US-9827226-B2 | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones | BEIGENE, LTD. (KY) | 2017-11-28 | — | — | US | disclosed |
| US-9827226-B2 | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones | BEIGENE, LTD. (KY) | 2017-11-28 | — | — | US | disclosed |
| US-9827226-B2 | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones | BEIGENE, LTD. (KY) | 2017-11-28 | — | — | US | disclosed |
| US-20170027912-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BEONE MEDICINES I GMBH (CH) | 2017-02-02 | — | — | US | disclosed |
| US-20170027912-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BEONE MEDICINES I GMBH (CH) | 2017-02-02 | — | — | US | disclosed |
| US-20170027912-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BEONE MEDICINES I GMBH (CH) | 2017-02-02 | — | — | US | disclosed |
| US-9393232-B2 | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones | BEIGENE, LTD. (KY) | 2016-07-19 | — | — | US | disclosed |
| US-9393232-B2 | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones | BEIGENE, LTD. (KY) | 2016-07-19 | — | — | US | disclosed |
| US-9393232-B2 | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones | BEIGENE, LTD. (KY) | 2016-07-19 | — | — | US | disclosed |
| US-20160030395-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BEONE MEDICINES I GMBH (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20160030395-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BEONE MEDICINES I GMBH (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20160030395-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BEONE MEDICINES I GMBH (CH) | 2016-02-04 | — | — | US | disclosed |
| WO-2014173241-A1 | SUBSTITUTED5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BEIGENE, LTD. (GB) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027912-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BRD4, BRPF3, BRD3 | BRD4 1/4885BRD2 7/4885BRD3 3/4885 |
| US-20160030395-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BRD4, BRPF3, BRD3 | BRD4 1/4885BRD2 7/4885BRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.